Lestaurtinib is cytotoxic to oxaliplatin-resistant transitional cell carcinoma cell line T24 in vitro

Pei Chun Lai, Te Chao Fang, Chuan Chu Cheng, Ted H. Chiu, Yen Ta Huang

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: Patients with bladder cancer have responded poorly to oxaliplatin therapy in clinical trials. Blockade of receptor tyrosine kinases is considered a good strategy in cancer therapy. Our previous studies have demonstrated the crucial roles of brain-derived neurotrophic factor and its receptor tropomyosin receptor kinase B (TrkB) in transitional cell carcinoma (TCC). The aim of this study was to examine the cytotoxic effects of lestaurtinib, a new pan-Trk inhibitor, and oxaliplatin on bladder cancer cell lines. Materials and Methods: BFTC905 and T24 TCC cell lines were used for investigation in vitro. The effects of oxaliplatin and/or lestaurtinib on cell viability, apoptosis, and expression of survivin and securin were assessed. MTT assay was used for cytotoxic evaluation. DNA fragments were detected in both the culture medium and cytoplasm to differentiate the types of cell death (apoptosis vs. necrosis). Western blots were used to analyze the expression of survivin and securin after oxaliplatin and/or lestaurtinib treatment. Results: Oxaliplatin at 3 μg/mL elicited cytotoxicity on BFTC905 but not T24 cells 48 hours after treatment. The addition of 1 or 3 μM lestaurtinib to oxaliplatin did not exert additive cytotoxic effects on BFTC905 cells. Although oxaliplatin at 3 μg/mL had no effect on T24 cells, the addition of 1 or 3 μM lestaurtinib demonstrated concentration-dependent inhibitory effects. Apoptosis of T24 cells was observed after treatment with lestaurtinib alone and lestaurtinib plus oxaliplatin. Furthermore, in T24 cells, the expression of survivin was inhibited by a combination of lestaurtinib and oxaliplatin, while securin expression was inhibited by lestaurtinib alone and lestaurtinib with oxaliplatin. Conclusion: Lestaurtinib may be a potential new drug for the targeted therapy of oxaliplatin-resistant TCC. Further in vivo studies are needed.

Original languageEnglish
Pages (from-to)125-130
Number of pages6
JournalTzu Chi Medical Journal
Volume22
Issue number3
DOIs
Publication statusPublished - Sep 2010
Externally publishedYes

Fingerprint

oxaliplatin
Transitional Cell Carcinoma
Cell Line
Securin
Apoptosis
Urinary Bladder Neoplasms
lestaurtinib
In Vitro Techniques
trkB Receptor

Keywords

  • Lestaurtinib
  • Oxaliplatin
  • Securin
  • Survivin
  • Transitional cell carcinoma

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lestaurtinib is cytotoxic to oxaliplatin-resistant transitional cell carcinoma cell line T24 in vitro. / Lai, Pei Chun; Fang, Te Chao; Cheng, Chuan Chu; Chiu, Ted H.; Huang, Yen Ta.

In: Tzu Chi Medical Journal, Vol. 22, No. 3, 09.2010, p. 125-130.

Research output: Contribution to journalArticle

Lai, Pei Chun ; Fang, Te Chao ; Cheng, Chuan Chu ; Chiu, Ted H. ; Huang, Yen Ta. / Lestaurtinib is cytotoxic to oxaliplatin-resistant transitional cell carcinoma cell line T24 in vitro. In: Tzu Chi Medical Journal. 2010 ; Vol. 22, No. 3. pp. 125-130.
@article{0dc214c9a6cb4dd1b2a4ea82613634ec,
title = "Lestaurtinib is cytotoxic to oxaliplatin-resistant transitional cell carcinoma cell line T24 in vitro",
abstract = "Objective: Patients with bladder cancer have responded poorly to oxaliplatin therapy in clinical trials. Blockade of receptor tyrosine kinases is considered a good strategy in cancer therapy. Our previous studies have demonstrated the crucial roles of brain-derived neurotrophic factor and its receptor tropomyosin receptor kinase B (TrkB) in transitional cell carcinoma (TCC). The aim of this study was to examine the cytotoxic effects of lestaurtinib, a new pan-Trk inhibitor, and oxaliplatin on bladder cancer cell lines. Materials and Methods: BFTC905 and T24 TCC cell lines were used for investigation in vitro. The effects of oxaliplatin and/or lestaurtinib on cell viability, apoptosis, and expression of survivin and securin were assessed. MTT assay was used for cytotoxic evaluation. DNA fragments were detected in both the culture medium and cytoplasm to differentiate the types of cell death (apoptosis vs. necrosis). Western blots were used to analyze the expression of survivin and securin after oxaliplatin and/or lestaurtinib treatment. Results: Oxaliplatin at 3 μg/mL elicited cytotoxicity on BFTC905 but not T24 cells 48 hours after treatment. The addition of 1 or 3 μM lestaurtinib to oxaliplatin did not exert additive cytotoxic effects on BFTC905 cells. Although oxaliplatin at 3 μg/mL had no effect on T24 cells, the addition of 1 or 3 μM lestaurtinib demonstrated concentration-dependent inhibitory effects. Apoptosis of T24 cells was observed after treatment with lestaurtinib alone and lestaurtinib plus oxaliplatin. Furthermore, in T24 cells, the expression of survivin was inhibited by a combination of lestaurtinib and oxaliplatin, while securin expression was inhibited by lestaurtinib alone and lestaurtinib with oxaliplatin. Conclusion: Lestaurtinib may be a potential new drug for the targeted therapy of oxaliplatin-resistant TCC. Further in vivo studies are needed.",
keywords = "Lestaurtinib, Oxaliplatin, Securin, Survivin, Transitional cell carcinoma",
author = "Lai, {Pei Chun} and Fang, {Te Chao} and Cheng, {Chuan Chu} and Chiu, {Ted H.} and Huang, {Yen Ta}",
year = "2010",
month = "9",
doi = "10.1016/S1016-3190(10)60056-0",
language = "English",
volume = "22",
pages = "125--130",
journal = "Tzu Chi Medical Journal",
issn = "1016-3190",
publisher = "財團法人中華民國佛教慈濟慈善事業基金會",
number = "3",

}

TY - JOUR

T1 - Lestaurtinib is cytotoxic to oxaliplatin-resistant transitional cell carcinoma cell line T24 in vitro

AU - Lai, Pei Chun

AU - Fang, Te Chao

AU - Cheng, Chuan Chu

AU - Chiu, Ted H.

AU - Huang, Yen Ta

PY - 2010/9

Y1 - 2010/9

N2 - Objective: Patients with bladder cancer have responded poorly to oxaliplatin therapy in clinical trials. Blockade of receptor tyrosine kinases is considered a good strategy in cancer therapy. Our previous studies have demonstrated the crucial roles of brain-derived neurotrophic factor and its receptor tropomyosin receptor kinase B (TrkB) in transitional cell carcinoma (TCC). The aim of this study was to examine the cytotoxic effects of lestaurtinib, a new pan-Trk inhibitor, and oxaliplatin on bladder cancer cell lines. Materials and Methods: BFTC905 and T24 TCC cell lines were used for investigation in vitro. The effects of oxaliplatin and/or lestaurtinib on cell viability, apoptosis, and expression of survivin and securin were assessed. MTT assay was used for cytotoxic evaluation. DNA fragments were detected in both the culture medium and cytoplasm to differentiate the types of cell death (apoptosis vs. necrosis). Western blots were used to analyze the expression of survivin and securin after oxaliplatin and/or lestaurtinib treatment. Results: Oxaliplatin at 3 μg/mL elicited cytotoxicity on BFTC905 but not T24 cells 48 hours after treatment. The addition of 1 or 3 μM lestaurtinib to oxaliplatin did not exert additive cytotoxic effects on BFTC905 cells. Although oxaliplatin at 3 μg/mL had no effect on T24 cells, the addition of 1 or 3 μM lestaurtinib demonstrated concentration-dependent inhibitory effects. Apoptosis of T24 cells was observed after treatment with lestaurtinib alone and lestaurtinib plus oxaliplatin. Furthermore, in T24 cells, the expression of survivin was inhibited by a combination of lestaurtinib and oxaliplatin, while securin expression was inhibited by lestaurtinib alone and lestaurtinib with oxaliplatin. Conclusion: Lestaurtinib may be a potential new drug for the targeted therapy of oxaliplatin-resistant TCC. Further in vivo studies are needed.

AB - Objective: Patients with bladder cancer have responded poorly to oxaliplatin therapy in clinical trials. Blockade of receptor tyrosine kinases is considered a good strategy in cancer therapy. Our previous studies have demonstrated the crucial roles of brain-derived neurotrophic factor and its receptor tropomyosin receptor kinase B (TrkB) in transitional cell carcinoma (TCC). The aim of this study was to examine the cytotoxic effects of lestaurtinib, a new pan-Trk inhibitor, and oxaliplatin on bladder cancer cell lines. Materials and Methods: BFTC905 and T24 TCC cell lines were used for investigation in vitro. The effects of oxaliplatin and/or lestaurtinib on cell viability, apoptosis, and expression of survivin and securin were assessed. MTT assay was used for cytotoxic evaluation. DNA fragments were detected in both the culture medium and cytoplasm to differentiate the types of cell death (apoptosis vs. necrosis). Western blots were used to analyze the expression of survivin and securin after oxaliplatin and/or lestaurtinib treatment. Results: Oxaliplatin at 3 μg/mL elicited cytotoxicity on BFTC905 but not T24 cells 48 hours after treatment. The addition of 1 or 3 μM lestaurtinib to oxaliplatin did not exert additive cytotoxic effects on BFTC905 cells. Although oxaliplatin at 3 μg/mL had no effect on T24 cells, the addition of 1 or 3 μM lestaurtinib demonstrated concentration-dependent inhibitory effects. Apoptosis of T24 cells was observed after treatment with lestaurtinib alone and lestaurtinib plus oxaliplatin. Furthermore, in T24 cells, the expression of survivin was inhibited by a combination of lestaurtinib and oxaliplatin, while securin expression was inhibited by lestaurtinib alone and lestaurtinib with oxaliplatin. Conclusion: Lestaurtinib may be a potential new drug for the targeted therapy of oxaliplatin-resistant TCC. Further in vivo studies are needed.

KW - Lestaurtinib

KW - Oxaliplatin

KW - Securin

KW - Survivin

KW - Transitional cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=78049504119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049504119&partnerID=8YFLogxK

U2 - 10.1016/S1016-3190(10)60056-0

DO - 10.1016/S1016-3190(10)60056-0

M3 - Article

AN - SCOPUS:78049504119

VL - 22

SP - 125

EP - 130

JO - Tzu Chi Medical Journal

JF - Tzu Chi Medical Journal

SN - 1016-3190

IS - 3

ER -